Status:
RECRUITING
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
Lead Sponsor:
West China Hospital
Conditions:
Infantile Hemangioma
Eligibility:
All Genders
1-4 years
Phase:
PHASE2
PHASE3
Brief Summary
The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).
Detailed Description
Infantile hemangioma (IH) is the most common benign tumor in infants, with an estimated prevalence of 4%-5%. Although most IH resolves over time without serious sequelae, a significant proportion can ...
Eligibility Criteria
Inclusion Criteria:
- all patients with ulcer IH;
- children with ulcer IH treated with propranolol.
Exclusion Criteria:
1) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with contraindications to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons.
-
Key Trial Info
Start Date :
May 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06798363
Start Date
May 2 2025
End Date
August 1 2026
Last Update
March 16 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041